Literature DB >> 34930034

Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

Alba Ruedas-López1, Isaac Alonso-García1, Cristina Lasarte-Monterrubio1, Paula Guijarro-Sánchez1, Eva Gato1, Juan Carlos Vázquez-Ucha1, Juan Andrés Vallejo1, Pablo Arturo Fraile-Ribot2, Begoña Fernández-Pérez2, David Velasco1, José María Gutiérrez-Urbón3, Marina Oviaño1, Alejandro Beceiro1, Concepción González-Bello4, Antonio Oliver2, Jorge Arca-Suárez1, Germán Bou1.   

Abstract

Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection. Fifteen isolates showing ceftolozane-tazobactam and ceftazidime-avibactam resistance were evaluated. Clinical conditions, previous positive cultures, and β-lactams received in the previous month were reviewed for each patient. MICs were determined by broth microdilution. Multilocus sequence types (MLSTs) and resistance mechanisms were determined using short- and long-read whole-genome sequencing (WGS). The impact of Pseudomonas-derived cephalosporinases (PDCs) on β-lactam resistance was demonstrated by cloning into an ampC-deficient PAO1 derivative (PAOΔC) and construction of 3D models. Genetic support of acquired β-lactamases was determined in silico from high-quality hybrid assemblies. In most cases, the isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Seven isolates from different sequence types (STs) owed their β-lactam resistance to chromosomal mutations and all displayed specific substitutions in PDC: Phe121Leu and Gly222Ser, Pro154Leu, Ala201Thr, Gly214Arg, ΔGly203-Glu219, and Glu219Lys. In the other eight isolates, the ST175 clone was overrepresented (6 isolates) and associated with IMP-28 and IMP-13, whereas two ST1284 isolates produced VIM-2. The cloned PDCs conferred enhanced cephalosporin resistance. The 3D PDC models revealed rearrangements affecting residues involved in cephalosporin hydrolysis. Carbapenemases were chromosomal (VIM-2) or plasmid-borne (IMP-28, IMP-13) and associated with class-1 integrons located in Tn402-like transposition modules. Our findings highlighted that cephalosporin/β-lactamase inhibitors are potential selectors of MDR/XDR P. aeruginosa strains producing PDC variants or metallo-β-lactamases. Judicious use of these agents is encouraged.

Entities:  

Keywords:  Pseudomonas aeruginosa; antibiotic resistance; beta-lactamases; beta-lactams; cephalosporin; mechanisms of resistance

Mesh:

Substances:

Year:  2021        PMID: 34930034      PMCID: PMC8846482          DOI: 10.1128/AAC.02067-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  41 in total

1.  Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.

Authors:  Sushmita D Lahiri; Grant K Walkup; James D Whiteaker; Tiffany Palmer; Kathy McCormack; M Angela Tanudra; Tory J Nash; Jason Thresher; Michele R Johnstone; Laurie Hajec; Stephania Livchak; Robert E McLaughlin; Richard A Alm
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

2.  Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem.

Authors:  Timothy A Blizzard; Helen Chen; Seongkon Kim; Jane Wu; Katherine Young; Young-Whan Park; Amy Ogawa; Susan Raghoobar; Ronald E Painter; Nichelle Hairston; Sang Ho Lee; Andrew Misura; Tom Felcetto; Paula Fitzgerald; Nandini Sharma; Jun Lu; Sookhee Ha; Emily Hickey; Jeff Hermes; Milton L Hammond
Journal:  Bioorg Med Chem Lett       Date:  2009-12-23       Impact factor: 2.823

3.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Gabriel Cabot; Xavier Mulet; Leonor Periañez; M Luisa Martín-Pena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

Review 5.  Metallo-beta-lactamases: the quiet before the storm?

Authors:  Timothy R Walsh; Mark A Toleman; Laurent Poirel; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

6.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

7.  Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.

Authors:  David M Livermore; Danièle Meunier; Katie L Hopkins; Michel Doumith; Robert Hill; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

Review 8.  New treatment options for multiresistant gram negatives.

Authors:  David L Paterson; Burcu Isler; Adam Stewart
Journal:  Curr Opin Infect Dis       Date:  2020-04       Impact factor: 4.915

9.  blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States.

Authors:  Mark A Toleman; Kenneth Rolston; Ronald N Jones; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.

Authors:  Melissa D Barnes; Magdalena A Taracila; Joseph D Rutter; Christopher R Bethel; Ioannis Galdadas; Andrea M Hujer; Emilia Caselli; Fabio Prati; John P Dekker; Krisztina M Papp-Wallace; Shozeb Haider; Robert A Bonomo
Journal:  mBio       Date:  2018-12-11       Impact factor: 7.867

View more
  3 in total

Review 1.  Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.

Authors:  Sisi Zhen; Hui Wang; Sizhou Feng
Journal:  Infection       Date:  2022-07-04       Impact factor: 3.553

Review 2.  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Antibiotics (Basel)       Date:  2022-02-20

3.  Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.

Authors:  María José Contreras-Gómez; José R W Martinez; Lina Rivas; Roberto Riquelme-Neira; Juan A Ugalde; Aniela Wozniak; Patricia García; José M Munita; Jorge Olivares-Pacheco; Manuel Alcalde-Rico
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.